Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP): Initial Review, 56803-56804 [2014-22533]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 184 / Tuesday, September 23, 2014 / Notices
who wishes to provide comments to the
Committee utilizing electronic data
projection submit the necessary material
to the Designated Federal Officer prior
to the close of business on November
10, 2014.
Dated: September 17, 2014.
James J. Berger,
Designated Federal Officer and Senior
Advisor for Blood and Tissue Safety Policy.
[FR Doc. 2014–22527 Filed 9–22–14; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Clinical Laboratory Improvement
Advisory Committee (CLIAC)
mstockstill on DSK4VPTVN1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC)
announces the following meeting of the
aforementioned committee:
Times and Dates: 8:30 a.m.–5:00 p.m.,
November 5, 2014; 8:30 a.m.–12:00 p.m.,
November 6, 2014.
Place: CDC, Century Center, 2500 Century
Parkway NE., Room 1200/1201, Atlanta,
Georgia 30345.
Status: Open to the public, limited only by
the space available. The meeting room
accommodates approximately 100 people.
This meeting will also be Webcast, please see
information below.
Purpose: This Committee is charged with
providing scientific and technical advice and
guidance to the Secretary of Health and
Human Services (HHS); the Assistant
Secretary for Health; the Director, Centers for
Disease Control and Prevention; the
Commissioner, Food and Drug
Administration (FDA); and the
Administrator, Centers for Medicare and
Medicaid Services (CMS). The advice and
guidance pertain to general issues related to
improvement in clinical laboratory quality
and laboratory medicine practice and specific
questions related to possible revision of the
Clinical Laboratory Improvement
Amendment (CLIA) standards. Examples
include providing guidance on studies
designed to improve safety, effectiveness,
efficiency, timeliness, equity, and patientcenteredness of laboratory services; revisions
to the standards under which clinical
laboratories are regulated; the impact of
proposed revisions to the standards on
medical and laboratory practice; and the
modification of the standards and provision
of non-regulatory guidelines to accommodate
technological advances, such as new test
methods and the electronic transmission of
laboratory information.
Matters for Discussion: The agenda will
include agency updates from CDC, CMS, and
FDA. Presentations and discussions will
include the FDA Draft Guidance on
VerDate Sep<11>2014
17:55 Sep 22, 2014
Jkt 232001
Laboratory Developed Tests; CLIA-waived
testing, including the process and criteria for
waiver approval; a report from the workgroup
charged with providing input to CLIAC
regarding the acceptability and application of
virtual cross-matching in lieu of serologic
cross-matching for transplantation; and
issues related to laboratory biosafety in the
United States.
Agenda items are subject to change as
priorities dictate.
Webcast: The meeting will also be
Webcast. Persons interested in viewing the
Webcast can access information at: https://
wwwn.cdc.gov/cliac/default.aspx
Online Registration Required: All people
attending the CLIAC meeting in-person are
required to register for the meeting online at
least 5 business days in advance for U.S.
citizens and at least 10 business days in
advance for international registrants. Register
at https://wwwn.cdc.gov/cliac/default.aspx by
scrolling down and clicking the link under
‘‘Meeting Registration’’ and completing all
forms according to the instructions given.
Please complete all the required fields before
submitting your registration and submit no
later than October 29, 2014 for U.S.
registrants and October 22, 2014 for
international registrants.
Providing Oral or Written Comments: It is
the policy of CLIAC to accept written public
comments and provide a brief period for oral
public comments whenever possible.
Oral Comments: In general, each
individual or group requesting to make oral
comments will be limited to a total time of
five minutes (unless otherwise indicated).
Speakers must also submit their comments in
writing for inclusion in the meeting’s
Summary Report. To assure adequate time is
scheduled for public comments, speakers
should notify the contact person below at
least one week prior to the meeting date.
Written Comments: For individuals or
groups unable to attend the meeting, CLIAC
accepts written comments until the date of
the meeting (unless otherwise stated).
However, it is requested that comments be
submitted at least one week prior to the
meeting date so that the comments may be
made available to the Committee for their
consideration and public distribution.
Written comments, one hard copy with
original signature, should be provided to the
contact person below, and will be included
in the meeting’s Summary Report.
Availability of Meeting Materials: To
support the green initiatives of the federal
government, the CLIAC meeting materials
will be made available to the Committee and
the public in electronic format (PDF) on the
internet instead of by printed copy. Check
the CLIAC Web site on the day of the meeting
for materials. Note: If using a mobile device
to access the materials, please verify that the
device’s browser is able to download the files
from the CDC’s Web site before the meeting.
https://wwwn.cdc.gov/cliac/cliac_meeting_
all_documents.aspx. Alternatively, the files
can be downloaded to a computer and then
emailed to the portable device. An internet
connection, power source and limited hard
copies may be available at the meeting
location, but cannot be guaranteed.
Contact Person for Additional Information:
Nancy Anderson, Chief, Laboratory Practice
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
56803
Standards Branch, Division of Laboratory
Science and Standards, Laboratory Science,
Policy and Practice Program Office, Office of
Surveillance, Epidemiology and Laboratory
Services, CDC, 1600 Clifton Road NE.,
Mailstop F–11, Atlanta, Georgia 30329–4018;
telephone (404) 498–2741; fax (404) 498–
2210; or via email at NAnderson@cdc.gov.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register Notices
pertaining to announcements of meetings and
other committee management activities, for
the Centers for Disease Control and
Prevention and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2014–22532 Filed 9–22–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Disease, Disability, and Injury
Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The Centers for Disease Control and
Prevention (CDC) Disease, Disability,
and Injury Prevention and Control
Special Emphasis Panel (SEP): Initial
Review, Epi-Centers for the Prevention
of Healthcare-Associated Infections,
Antimicrobial Resistance and Adverse
Events, Funding Opportunity
Announcement (FOA) CK11–
0010401SUPP14, held an initial review
of applications on June 3, 2014. Due to
administrative oversight, a notice was
not published in the Federal Register.
A notice should have published prior
to May 16, 2014 according to the 15 day
notice requirement of the Federal
Advisory Committee Act (FACA)
https://intranet.cdc.gov/maso/cmppa/
pdfs/faca.pdf and the GSA Final Rule
https://www.gsa.gov/graphics/ogp/
FACAFinalRule_R2E-cNZ_0Z5RDZi34K-pR.pdf.
The intent of 15 day prior notice is to
advise the public of scheduled meetings
open to the public. The meeting of June
3, 2014 was a closed meeting, having
met the standard for exemptions to open
meeting requirements due to the
personal and/or proprietary information
included in grant applications. Public
participation was not impacted as a
result of the notice not getting
published.
Contact Person for More Information:
Catherine Ramadei, Acting Chief,
Federal Advisory Committee
Management Branch, Management
E:\FR\FM\23SEN1.SGM
23SEN1
56804
Federal Register / Vol. 79, No. 184 / Tuesday, September 23, 2014 / Notices
Analysis and Services Office, 1600
Clifton Rd. NE., MS: K–48, Atlanta, GA
30329, email: cyr9@cdc.gov.
The Director, Management Analysis
and Services Office, has been delegated
the authority to sign Federal Register
notices pertaining to announcements of
meetings and other committee
management activities, for both the
Centers for Disease Control and
Prevention, and Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2014–22533 Filed 9–22–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
Board of Scientific Counselors,
National Center for Health Statistics
(BSC, NCHS)
mstockstill on DSK4VPTVN1PROD with NOTICES
In accordance with section 10(a)(2) of
the Federal Advisory Committee Act
(Pub. L. 92–463), the Centers for Disease
Control and Prevention (CDC), National
Center for Health Statistics (NCHS)
announces the following meeting of the
aforementioned committee:
Times and Dates: 11:00 a.m.–5:30 p.m.,
October 29, 2014; 8:30 a.m.–1:00 p.m.,
October 30, 2014.
Place: NCHS Headquarters, 3311 Toledo
Road, Hyattsville, Maryland 20782.
Status: This meeting is open to the public;
however, visitors must be processed in
accordance with established federal policies
and procedures. For foreign nationals or nonU.S. citizens, pre-approval is required (please
contact Gwen Mustaf, 301–458–4500, glm4@
cdc.gov, or Virginia Cain, vcain@cdc.gov at
least 10 days in advance for requirements).
All visitors are required to present a valid
form of picture identification issued by a
state, federal or international government. As
required by the Federal Property
Management Regulations, Title 41, Code of
Federal Regulation, Subpart 101–20.301, all
persons entering in or on Federal controlled
property and their packages, briefcases, and
other containers in their immediate
possession are subject to being x-rayed and
inspected. Federal law prohibits the knowing
possession or the causing to be present of
firearms, explosives and other dangerous
weapons and illegal substances. The meeting
room accommodates approximately 100
people.
Purpose: This committee is charged with
providing advice and making
recommendations to the Secretary,
Department of Health and Human Services;
the Director, CDC; and the Director, NCHS,
regarding the scientific and technical
VerDate Sep<11>2014
17:55 Sep 22, 2014
Jkt 232001
program goals and objectives, strategies, and
priorities of NCHS.
Matters for Discussion: The agenda will
include:
1. Welcome remarks by the Director, NCHS
2. National Health & Nutrition Examination
Survey DNA Collection Plans
3. Office of Research and Methodology
update
4. National Health Interview Survey Sexual
Orientation Data presentation
Requests to make oral presentations should
be submitted in writing to the contact person
listed below. All requests must contain the
name, address, telephone number, and
organizational affiliation of the presenter.
Written comments should not exceed five
single-spaced typed pages in length and must
be received by October 17, 2014.
The agenda items are subject to change as
priorities dictate.
Contact Person for More Information:
Virginia S. Cain, Ph.D., Director of
Extramural Research, NCHS/CDC, 3311
Toledo Road, Room 7208, Hyattsville,
Maryland 20782, Telephone: (301) 458–4500,
Fax: (301) 458–4024.
The Director, Management Analysis and
Services Office, has been delegated the
authority to sign Federal Register notices
pertaining to announcements of meetings and
other committee management activities for
both CDC and the Agency for Toxic
Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and
Services Office, Centers for Disease Control
and Prevention.
[FR Doc. 2014–22529 Filed 9–22–14; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[CDC–2014–0014, Docket Number NIOSH–
275]
Proposed National Total Worker
HealthTM Agenda
National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC),
Department of Health and Human
Services (HHS).
ACTION: Notice of opportunity to provide
oral comments at three town-hall
sessions, and the opportunity to provide
written comments.
AGENCY:
The National Institute for
Occupational Safety and Health
(NIOSH) of the Centers for Disease
Control and Prevention (CDC)
announces the opportunity for comment
on the Proposed National Total Worker
HealthTM Agenda. To view the Agenda
and submit written comments, visit,
SUMMARY:
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
www.regulations.gov, and enter CDC–
2014–0014 in the search field and click
‘‘Search.’’ There is also an opportunity
to submit oral comments at one of three
town-hall sessions during the following
two scientific meetings: The 1st
International Symposium to Advance
Total Worker HealthTM and The
Healthier Federal Workers Conference.
For information on how to register for
the conferences and town-hall sessions
see the Supplementary Section. All
comments are welcome, but NIOSH
specifically seeks those that address the
following questions:
• Do you see your own organization’s
goals reflected in the Proposed National
Total Worker HealthTM Agenda?
• What are the bridges between your
own work and the Proposed National
Total Worker HealthTM Agenda?
• Are there any missing components
or gaps in the Proposed National Total
Worker HealthTM Agenda?
DATES:
Meeting date and time:
(1) October 6–8, 2014; 2 town-hall
sessions: October 7, 2014, 12:30–
1:45 p.m. Eastern Time and 5–6:15
p.m. Eastern Time
(2) October 9, 2014, 1:15–2:30 p.m.
Eastern Time
Registration to speak: Participants
who wish to speak during one of the
town-hall sessions must register by
sending an email to stamers@cdc.gov by
October 1, 2014.
Public comment period: Comments
must be received by December 22, 2014.
ADDRESSES: Both meetings will be held
at the National Institutes of Health,
Natcher Conference Center (Bldg. 45),
9000 Rockville Pike, Bethesda,
Maryland 20892.
Security Considerations: Due to
mandatory security clearance
procedures, in-person attendees must
present valid government-issued picture
identification (passport for non-U.S.
citizens) to security personnel upon
entering the NIH Campus.
You may submit comments, identified
by CDC–2014–0014 and Docket Number
NIOSH–275, by one of the following
three methods:
• Internet: https://
www.regulations.gov. Enter CDC–2014–
0014 in the search field and click
‘‘Search.’’
• Mail: National Institute for
Occupational Safety and Health, NIOSH
Docket Office, 1090 Tusculum Avenue,
MS C–34, Cincinnati, Ohio 45226–1998.
Identify the submission for NIOSH
Docket-275.
• In-person: Only individuals who
are registered for one and/or both
conferences and one of three town-hall
E:\FR\FM\23SEN1.SGM
23SEN1
]]>Agencies
[Federal Register Volume 79, Number 184 (Tuesday, September 23, 2014)]
[Notices]
[Pages 56803-56804]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-22533]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
Disease, Disability, and Injury Prevention and Control Special
Emphasis Panel (SEP): Initial Review
The Centers for Disease Control and Prevention (CDC) Disease,
Disability, and Injury Prevention and Control Special Emphasis Panel
(SEP): Initial Review, Epi-Centers for the Prevention of Healthcare-
Associated Infections, Antimicrobial Resistance and Adverse Events,
Funding Opportunity Announcement (FOA) CK11-0010401SUPP14, held an
initial review of applications on June 3, 2014. Due to administrative
oversight, a notice was not published in the Federal Register.
A notice should have published prior to May 16, 2014 according to
the 15 day notice requirement of the Federal Advisory Committee Act
(FACA) https://intranet.cdc.gov/maso/cmppa/pdfs/faca.pdf and the GSA
Final Rule https://www.gsa.gov/graphics/ogp/FACAFinalRuleR2E-
cNZ0Z5RDZ-i34K-pR.pdf.
The intent of 15 day prior notice is to advise the public of
scheduled meetings open to the public. The meeting of June 3, 2014 was
a closed meeting, having met the standard for exemptions to open
meeting requirements due to the personal and/or proprietary information
included in grant applications. Public participation was not impacted
as a result of the notice not getting published.
Contact Person for More Information: Catherine Ramadei, Acting
Chief, Federal Advisory Committee Management Branch, Management
[[Page 56804]]
Analysis and Services Office, 1600 Clifton Rd. NE., MS: K-48, Atlanta,
GA 30329, email: cyr9@cdc.gov.
The Director, Management Analysis and Services Office, has been
delegated the authority to sign Federal Register notices pertaining to
announcements of meetings and other committee management activities,
for both the Centers for Disease Control and Prevention, and Agency for
Toxic Substances and Disease Registry.
Claudette Grant,
Acting Director, Management Analysis and Services Office, Centers for
Disease Control and Prevention.
[FR Doc. 2014-22533 Filed 9-22-14; 8:45 am]
BILLING CODE 4163-18-P
